Cypress Wealth Services LLC Buys 138 Shares of Novartis AG $NVS

Cypress Wealth Services LLC lifted its stake in shares of Novartis AG (NYSE:NVS) by 7.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,122 shares of the company’s stock after acquiring an additional 138 shares during the quarter. Cypress Wealth Services LLC’s holdings in Novartis were worth $257,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Essex Savings Bank boosted its stake in Novartis by 1.9% during the 2nd quarter. Essex Savings Bank now owns 4,611 shares of the company’s stock valued at $558,000 after purchasing an additional 85 shares during the period. Physician Wealth Advisors Inc. boosted its stake in Novartis by 5.8% during the 2nd quarter. Physician Wealth Advisors Inc. now owns 1,541 shares of the company’s stock valued at $186,000 after purchasing an additional 85 shares during the period. Gallacher Capital Management LLC boosted its stake in Novartis by 1.7% during the 2nd quarter. Gallacher Capital Management LLC now owns 5,371 shares of the company’s stock valued at $650,000 after purchasing an additional 92 shares during the period. Ascent Group LLC boosted its stake in Novartis by 0.7% during the 2nd quarter. Ascent Group LLC now owns 14,121 shares of the company’s stock valued at $1,709,000 after purchasing an additional 97 shares during the period. Finally, Sage Rhino Capital LLC boosted its stake in Novartis by 1.2% during the 2nd quarter. Sage Rhino Capital LLC now owns 8,120 shares of the company’s stock valued at $983,000 after purchasing an additional 99 shares during the period. Institutional investors own 13.12% of the company’s stock.

Novartis Price Performance

Shares of NVS stock opened at $130.31 on Wednesday. The stock has a 50 day moving average of $125.62 and a two-hundred day moving average of $118.16. The company has a current ratio of 0.82, a quick ratio of 0.62 and a debt-to-equity ratio of 0.53. Novartis AG has a 12 month low of $96.06 and a 12 month high of $133.55. The company has a market capitalization of $275.27 billion, a P/E ratio of 18.97, a P/E/G ratio of 1.79 and a beta of 0.64.

Novartis (NYSE:NVS) last issued its earnings results on Thursday, July 17th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Novartis had a return on equity of 41.08% and a net margin of 25.64%.The business had revenue of $14.05 billion during the quarter, compared to analysts’ expectations of $13.94 billion. During the same period in the prior year, the firm posted $1.97 EPS. Novartis’s quarterly revenue was up 12.3% compared to the same quarter last year. As a group, equities analysts expect that Novartis AG will post 8.45 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Novartis in a research note on Thursday, August 21st. Morgan Stanley upgraded Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 target price for the company in a research note on Friday, August 8th. The Goldman Sachs Group reiterated a “sell” rating and issued a $118.00 price objective (down previously from $119.00) on shares of Novartis in a research report on Friday, September 12th. Wall Street Zen upgraded Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Novartis presently has an average rating of “Hold” and an average target price of $120.33.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.